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13492 | Chem. Sci., 2021, 12, 13492–1tive SARS-CoV-2 helicase complex
as a basis for structure-based inhibitor design†
Dénes Berta, ‡ab Magd Badaoui, ‡ab Sam Alexander Martino, ab
Pedro J. Buigues, ab Andrei V. Pisliakov, *c Nadia Elghobashi-Meinhardt, *d
Geoff Wells, *e Sarah A. Harris, *f Elisa Frezza *g and Edina Rosta *ab
The RNA helicase (non-structural protein 13, NSP13) of SARS-CoV-2 is essential for viral replication, and it is
highly conserved among the coronaviridae family, thus a prominent drug target to treat COVID-19. We
present here structural models and dynamics of the helicase in complex with its native substrates based
on thorough analysis of homologous sequences and existing experimental structures. We performed and
analysed microseconds of molecular dynamics (MD) simulations, and our model provides valuable
insights to the binding of the ATP and ssRNA at the atomic level. We identify the principal motions
characterising the enzyme and highlight the effect of the natural substrates on this dynamics.
Furthermore, allosteric binding sites are suggested by our pocket analysis. Our obtained structural and
dynamical insights are important for subsequent studies of the catalytic function and for the
development of specific inhibitors at our characterised binding pockets for this promising COVID-19
drug target.Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
is the causative agent of COVID-19 disease and is responsible
for the largest modern pandemic. The virus is closely related to
SARS-CoV and MERS-CoV that caused smaller outbreaks of
disease earlier this century.1 Currently, only a few approved
drugs have been repurposed for the disease.2 The approved
treatments can be categorized into three groups: aiding respi-
ration in severe cases, repurposed antiviral drugs and mono-
clonal antibodies. Remdesivir has the longest history of use
against COVID-19 infection and shown to bind to the RNA
dependent RNA polymerase (RdRp),3,4 although recent trial dataiversity College London, London, WC1E
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3505found no evidence for improvement in patient conditions.5
Further efforts include trials of antiviral combination thera-
pies,6 or use of the anti-leprosy drug clofazimine, the latter has
been found to inhibit helicase activity.7 However, there is a need
for development of specic compounds that can be used to
inhibit viral replication for the treatment of COVID-19,
prophylaxis of vulnerable individuals and to add to the reper-
toire of treatment for future coronavirus outbreaks.
Here we focus on determining the structure of catalytically
active complexes of the SARS-CoV-2 RNA helicase, also known
as non-structural protein 13 (NSP13) (Fig. 1). This protein is part
of the Orf1ab polyprotein, that is spliced to produce the
enzymes required for viral replication. The RNA helicase
performs two essential functions for the viral replication
making it an ideal drug target. It is thought to perform the rst
step in the 50-capping of the viral RNA by its triphosphatase
function hydrolysing the 50-triphosphate group to form
diphosphate-RNA.8,9 Furthermore, its main helicase function
enables RNA translocation and unwinding in an ATP-dependent
mechanism during viral replication.
Accordingly, numerous studies have already demonstrated
that it is possible to develop potent inhibitors of viral helicases
as antiviral agents.10 The 2003 SARS epidemic inspired a wave of
drug development, oen in conjunction with other positive RNA
viral targets such as the hepatitis C virus (HCV).11–14 Conse-
quently, HCV helicase inhibitory aryl diketoacids (ADKs) were
found useful against SARS-CoV,11,12,15 in addition to porphyrin
metal complexes,16 and natural14 or synthetic products.13,17–19
Typically, these compounds inhibit both the unwinding and the© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 1 (a) Our model of the RNA helicase NSP13 of SARS-CoV-2 monomer (cartoon) coloured by three domains: RecA1 (yellow), RecA2
(magenta), and Domain 1 (aquamarine). ATP analogues (sticks) along with Mg (green sphere) and single stranded nucleic acids are depicted from
aligned homologous structures (full list of PDB codes are available in Table S1†). 30 ends of the nucleic acids present the same orientation in all
chains (highlighted in green). (b) Position of the ATP analogues (nucleotides in stick and metal ions and compounds in spheres) in homologous
structures. (c) Specific helicase inhibitor binding region with allosteric inhibitors displayed in cyan (black arrow).


























































































View Article OnlineNTPase activity of the coronaviral helicase, but there are rare
examples for selectively hindering the unwinding,13 or the NTP
hydrolysis.14 Only a few of these efforts were based on or
considered structural information. Notably, Hoffmann et al.
build a homology model and proposed some lead compounds
that may interact with the ATP site.20 Based on the effort on the
SARS-CoV helicase, similar approaches can be applied to the
highly homologous SARS-CoV-2 helicase.7
Coronaviral RNA helicases share a high similarity. 600 out of
the 601 residues of the SARS-CoV-2 RNA helicase are identical to
those of the SARS-CoV virus, and 70% match that of the MERS-
CoV NSP13, demonstrating that these proteins are highly
conserved within the coronaviridae family. Recently, a set of
deposited structures from the PanDDA analysis group (to be
published) deposited 51 high resolution crystal structure of the
apo SARS-CoV-2 helicases in complex with a library of small
molecule fragment analogues.Helicase structures and models
The rst SARS-CoV-2 helicase structure (PDB ID 6zsl) was depos-
ited in July 2020 and the almost identical SARS-CoV helicase
structure in 2019 (PDB ID 6jyt),21 both resolved as crystallographic
dimers (Fig. 2a and b). Interestingly, the dimerization interface is© 2021 The Author(s). Published by the Royal Society of Chemistrydifferent in the two cases, leading to structurally dissimilar
complexes. Recent worksmainly focusing on the RdRp NSP12,22,23
which is expressed in the polyprotein sequence just before the
helicase, also yielded structures of the replication machinery,
including low resolution cryo-EM images of the helicase. In the
cryo-EM structure of the RdRp complexed with the RNA helicase
(and cofactors NSP7 and NSP8), the two helicase protomers
mainly interact with NSP8 (Fig. 2c).4 The helicase chains were
resolved using the apo helicase 6jyt as a template for the cryo-EM
density maps and rened using soware algorithms.23 Unfortu-
nately, the 3.7 Å resolution is too low in this structure to resolve
the ATP pocket in a catalytically competent conformation.
A more recent high resolution (2.90 Å) cryo-EM work of Lou
et al., presents a partial structure of the replication and tran-
scription complex (RTC) (Fig. 2d).24 The complex includes the
RdRp, NSP7, NSP8 and two helicase NSP13 protein copies, with
one of the helicases in complex with a single-stranded RNA
(ssRNA) fragment. Considering these structure, we conclude
that catalytically active form of the helicase is a monomer
within the larger RTC complex, and the crystallized homodi-
meric forms are not the biologically functional unit. Even more
recently, a structure (PDB ID 7NNO) was released as amonomer,
binding an ATP analogue ANP. The active site agrees with our
model, however, this structure does not host ssRNA.Chem. Sci., 2021, 12, 13492–13505 | 13493
Fig. 2 Structural comparison of the deposited PDB structures of the helicase dimer in SARS-CoV-1 (PDBID: 6jyt, a), SARS-CoV-2 (PDBID: 6zsl, b),
SARS-CoV-2 in complex with NSP7 NSP8 and NSP12 (PDBID: 6xez, c) and SARS-CoV-2 with a small fragment of ssRNA bound in complex with
NSP7 NSP8 and NSP12 (PDBID: 7cxm, d). The interaction between the two helicase monomers differs depending on the experimental method
used to resolve the structures.


























































































View Article OnlineAlthough more attention is directed to targeting the
RdRp22,25–27 or the main protease,28–32 as these are suggested to
be more susceptible for binding an inhibitor,33–35 the helicase is
also subject to modelling and docking studies. Crucially,
however, the pharmacophore and docking studies of the heli-
case start from the homologous SARS-CoV crystal structure
(Fig. 2a)36–40 or the counterpart in SARS-CoV-2 (Fig. 2b),41 which
are both apo, lacking the ATP and the ssRNA from the complex.
MD simulations are also available with ATP and ssRNA that
used a docking approach to identify promising bound ligands at
the ATP binding site.42
Here we present a computational model of the SARS-CoV-2
RNA helicase with ATP and ssRNA substrates bound. We per-
formed sequence similarity searches to identify key domains and
homologous sequences suggesting structurally important
conserved motifs. We also performed structural alignments of
available homologous helicase crystal structures to help position13494 | Chem. Sci., 2021, 12, 13492–13505the bound RNA and ATP substrates (Fig. 1b). Using both Amber
and CHARMM force elds, we carried out long timescale MD
simulations of both the apo and the substrate bound states to
address the exibility and the stability of our catalytically
competent structures. We analysed the differences in the
dynamics between the apo and the holo structures using Principal
Component Analysis (PCA). We identied the substrate and allo-
steric binding pockets and developed an implementation to
follow their dynamical behaviour during the MD simulations. We
demonstrate novel pockets, including ones that are coronaviridae-
specic. Our results will help guide ongoing drug development.
Methods
Homology modelling
Proteins with crystal structures were aligned with MUSTANG for
a combined structural-sequence alignment.43 The apo SARS-© 2021 The Author(s). Published by the Royal Society of Chemistry


























































































View Article OnlineCoV-2 helicase structure was based on PBD ID 6jyt.21 Missing
residues were added and the I570V replacement were carried
out in Pymol 2.3.0.44 The positions of the Mg2+ and ATP were
determined using the coordinates of PDB ID 2xzo,45 as
a template. Crystallographic water residues were also taken
from 2xzo as well as residues around the ATP pocket (loops 284–
289 and 534–541, Gln404 and Arg443), except for Arg442 which
was modelled based on PBD ID 6jim.46 The ssRNA was posi-
tioned based on 2xzl.45 The protonation state of titratable resi-
dues were estimated by PROPKA 3.0 (Tables S2 and S3†).47,48Molecular dynamics
We performed multiple unbiased MD simulations of the heli-
case in its apo and holo complex. For a detailed explanation of
the methods used to parametrize and run the simulations,
please refer to the ESI note 1 and Table S4† for a list of all
simulations. We performed the MD using three independent
force eld setups: (1) CHARMM36 combined with TIP3P water
potential (CHARMM), (2) Amber14SB for the protein, Amber
ff99 + parmbsc0 + chioL3 for the ssRNA and TIP3P for water
(Amber), and (3) Amber14SB protein force eld combined with
ff99OL3 for the RNA and TIP3P for water. We compared the
simulations produced with (1) and (2) as part of the analysis and
check the convergency by calculating the RMSD (Fig. S1†).Pocket analysis
MD trajectories were sampled at 1 ps intervals and stripped of
all non-protein residues for pocket analysis. All pockets above
the volume of 200 Å3 were obtained by using pyvol,49 with
default parameters (sphere radius 1.4–3.4). Pocket equivalency
across frames were based on Euclidean distance measured from
every tenth a carbon of the protein backbone.Principal component analysis
We used PCA to assess the conformational changes observed in
the monomer molecular dynamics simulations.50 The analysis
was restricted to the a-carbon protein atoms to reduce the
dimensionality of the dataset,51 and the protein chain was
truncated to limit the contribution of end effects.
The data was grouped by the force-eld used (CHARMM/
Amber), and whether it was an apo or holo structure. The PCA
was performed on these large groups using the scikit-learn
library.52,53 Before the decomposition, each protomer in each
frame from each simulation was aligned via RMSD minimiza-
tion to a reference structure from the equilibrated holo model.
Weighted RMSD modes Ni were calculated to show the
contribution of each of the m residues to the ith PCA mode
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CCCCCA© 2021 The Author(s). Published by the Royal Society of ChemistryWhere li is the i
th eigenvalue, and the vector rows correspond
to the coordinates describing the positions of each of the m a-
carbon atoms. Component-wise decomposition of this vector
gives a quantitative assessment of how much each residue
inuences the respective PCA mode.
We used dynamic cross-correlation (DCC) map analysis to












Where ri(t) is the ith atoms coordinates at time t, hxit denotes
the time ensemble average of the quantity x, and Dri(t) ¼ ri(t) 
hri(t)ti.
This equation yields a scalar quantity Cij for each pair of
atoms, in the range 1 to 1. The closer the value to 1, the more
the displacement of atom i is correlated to that of j. Similarly,
a negative value indicates an inverse correlation between the
two displacements, and a zero value indicates there is no
correlation. The maps indicate which residues are displaced
together, highlighting groups of residues that move as larger
units.Dynamic weighted histogram analysis method (DHAM)
To calculate the free energy surface for the protein conforma-
tional landscape corresponding to key dynamical variables, we
constructed a discretized two-dimensional grid to determine
Markov State Models (MSMs).56 The collective variables were
extracted along the trajectory, by calculating parameters,
including inter-atomic distances, puckering angles, PCA
components and pocket volumes. The 2D free energy surfaces
are calculated from the rst eigenvectors of the MSMs, and
provide thermodynamic information on the collective variables
used.Results
Helicase domains and their sequence homology
The single-chain SARS-CoV-2 helicase can be divided into ve
domains.21 The sequence starts with Domain 1 (residues 1–260),
which features: a Zinc-binding domain (ZBD, residues 1–100),
known to facilitate nucleic acid recognition;57 a Stalk region
shaped by 2 contiguous alpha helices (residues 100–150) which
functions as an interface connecting the ZBD with Domain 1B
(residues 150–260) that interacts with the ssRNA. For simplicity,
we refer to domain one as these three combined (Fig. 1, aqua-
marine cartoon). The rest of the chain is divided into RecA1 and
RecA2 domains,58 which are well characterized in the super-
family 1B-type helicases and interact with ATP at their interface
(Fig. 1, yellow and magenta cartoon, respectively).
We have obtained the most homologous 957 sequences and
their alignments from the UniProtKB library.59 The pairwise
alignments showed awed identication of RecA1 (see Fig. S2†),
therefore we proceeded to optimize a multiple sequence align-
ment (MSA).60 Firstly, we clustered the obtained sequences toChem. Sci., 2021, 12, 13492–13505 | 13495


























































































View Article Onlineavoid overrepresenting highly similar entries.61 The full list of
796 clusters is available in the ESI note 2.
A set of 52 of these clusters and their representative
sequences show similarity across the whole helicase sequence
and match at least half of the helicase in the MSA (Fig. 3a, lime
region). These represent 96 sequences, all derived from coro-
naviruses, primarily originate from human and bat viromes
(beta and alphacoronaviruses),62 and infect various hosts in the
animal kingdom, including humans. Intriguingly, the next best
sequence alignment only matches 107 amino acids; most of
these and subsequent aligned regions are specic to the RecA
domains and span all types of proteins from various organisms
(Fig. 3a blue region).Fig. 3 (a) Distribution of the identity of sequences in multiple sequen
members of coronaviridae above 300matching residues (50%, lime circle
similar residues, red circles). The mass of the sequences matches only
represented by 52) are grouped in coronavirus subfamilies (grouped in
identity of the representative sequences of 796 clusters from UniProtKB
shows similarity only to the close relatives (52 sequences, representing c
across ATPase sequences. Key structural motifs are highlighted using sy
black triangle, ssRNA interactions: red triangles).
13496 | Chem. Sci., 2021, 12, 13492–13505To evaluate any similarities to Domain 1 only, we also per-
formed a search using only the rst 230 residues. This search
for sequences that match at least 70 residues resulted in the
exact same 96 sequences as before, exclusively belonging to
coronaviridae. An additional 21 sequences match only shorter
segments of the sequence between residues 1–230, corre-
sponding to a 22% sequence identity or below.
The MSA also enables us to see which regions and motifs are
conserved in the SARS-CoV-2 helicase sequence. Domain 1 only
exhibits a few residues apparently with higher conservation (at
positions 87, 124 and 235), however, these are likely to be only
random matches, as the corresponding alignments are domi-
nated by non-coronaviral sequences, and not aligned well to thece alignment compared to the SARS-CoV-2 helicase. There are only
s, 52 entries). There are no sequences withmedium similarity (107–300
107 residues or less (blue circles). The closest relatives (96 sequences
the y axis) with principal hosts highlighted in the inset. (b) Sequence
aligned to the 601-residue long SARS-CoV-2 RNA helicase. Domain 1
lusters of 96), while the RecA1 and RecA2 domains are more common
mbols (P-loop: grey square, DE motif: green square, arginine fingers:
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 4 Modelling and conservation of the ATP and RNA sites. (a) Main protein-substrate interactions of the triphosphate andmagnesium ions are
compared with alignment for PDB template 2xzo (cyan lines). (b) Nucleotide-binding region focusing on Arg442 (magenta sticks) is aligned with
homologous arginine residues (lines, PDB structures 5k8u, 5vhc, 5xdr, 5y4z, 5 y6m, 5y6n, 6adx, 6ady, 6c90 and 6jim). (c) Sequence conservation
for RecA1 (orange) and RecA2 (magenta) domains are depicted in logos for each residue and its neighbours (data from Fig. 3b). Coloured letters
represent the residues in the SARS-CoV-2 helicase sequence, depicted residue indices are bold in the logos. (d) Structures of the RNA binding
region aligned with existing RNA-helicase crystal structures complexed with ssRNA (depicted in lines). RecA1 and RecA2 domains are shown in
yellow and magenta, respectively. Key residues (sticks) are labelled, and H-bonds are depicted in yellow dashes.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 13492–13505 | 13497





















































































































































































View Article Onlineneighbouring residues of the SARS-CoV-2 helicase sequence.
The RecA domains, which are members of the AAA 30 and AAA
12 families, are more common in various ATP-binding struc-
tures and the MSA indeed sheds light upon important binding
motifs such as the P-loop (Fig. 3b, grey squares) the DE motif
(Fig. 3b, green squares) and the arginine ngers (Fig. 3b, black
triangles). Furthermore, we identied several residues involved
in RNA binding (Fig. 3b, red triangles) which are also conserved
structurally in homologous PDB entries. Finally, the GDP(A)Q
loop at position 400–404 with high consensus in the MSA
features a glutamine potentially involved in the proton transfer
during the ATP hydrolysis. This motif bridges the g-phosphate
end of the ATP pocket and the RNA binding site; therefore we
suggest that it may be involved in coupling the hydrolysis of ATP
to the changes induced by the hydrolysis inducing the RNA
translocation.
Among crystal structures containing ATP analogues, most
helicases have very low sequence similarity to NSP13. The
closest homologues are 2xzo, 5mzn, and 6jim with 11.0%,
10.2%, and 8.4% sequence identity, respectively. Despite the
low sequence identity, most residues in the ATP binding pocket
are conserved. At the same time, the closest human sequence
homologue based on our homology search, ZGRF1, a putative
RNA helicase, shares only 22% sequence similarity, restricted to
the RecA1 and RecA2 domains. This relatively narrow band-
width of sequence similarity may be advantageous to the design
of specic inhibitors against the coronavirus RNA helicases that
do not inhibit human proteins.Structural model of the ATP binding site
We modelled the ATP-bound active site of the SARS-CoV-2 heli-
case using the 2xzo structure as a template.45 The essential Mg2+
ion cofactor coordinates both the b- and g-phosphates and
a conserved Ser288 (Fig. 4a and c). The active site contains a DE of
the DEAD-motif of RNA helicases. The conserved Asp374 H-
bonds with Ser288 and one of the Mg-coordinating water mole-
cules, whereas the Glu375 is positioned as the proton
acceptor.20,63,64 The g-phosphate is stabilized via electrostatic
interactions and H-bonds with Arg567 Lys289 and Gln404
through a water molecule, which are also found in 95, 56 and
57% of the homologous sequences analysed, respectively. The b-
phosphate forms a H-bond with Arg443. Unlike the highly
conserved residues recognizing the triphosphate pocket, the
environment of the sugar and purine moieties (Fig. 4b and c)
shows a greater diversity. The ATP ribose is likely to interact with
Glu540 and Lys320 as seen in ten and four homologous PDB
structures, respectively. The purine ring is stabilized through
multiple p stacking interactions, from one side with Arg442 (a p-
cation interaction), in some helicases this interaction is fullled
with a tyrosine residue; from the other side with His290 and
Phe261. Additionally, there is a H-bond between the exocyclic
amino group of the purine with Asn265, a residue which is more
typically served by a glutamine in similar sequences.
A lack of specicity towards the purine group is likely due to
the dual function of the SARS-CoV-2 helicase to aid the 50-
capping of the RNA by the triphosphate hydrolysis of most NTP13498 | Chem. Sci., 2021, 12, 13492–13505substrates.9 Due to these major differences, this area of the
nucleotide-binding pocket may be useful in the design of SARS-
CoV-2-specic antiviral drugs.Structural model of the RNA binding
site
The most signicant changes between the holo and apo struc-
tures are related to the binding of the large ssRNA substrate.
This substrate binding is more challenging to model, partly due
to potential force eld inaccuracies, and partly also due to the
less specic interactions between the protein and the RNA
sidechain that has to accommodate a range of viral sequences
for the unwinding and translocation function of the helicase.
Despite the relatively large size of the ssRNA substrate, we did
not observe large scale domainmovements in the holo structure
compared to the apo. We observed more localized conforma-
tional changes: only the loop of residues 482–487 and the C
terminus of RecA2 domain changed considerably compared to
the apo structure.
Filtering the related crystal structures those containing
nucleic acids (NAs), we noticed that their directionality relative to
the ATP pocket is well dened (Fig. 1a and c). Domain 1, being in
contact with the sidechain of the ssRNA, does not feature specic
motifs, thus allowing different RNA bases to translocate. A long
loop transitions into the RecA1 and 2 domains sandwiching the
ATP pocket on the side of the ssRNA backbone. This region,
equipped with the necessary functionalities to perform the ATP
hydrolysis, has a higher degree of conservation along the heli-
cases. Both RecA domains have specic residues that contact
ssRNA phosphates, depicted in Fig. 4c and d. Thr359 in RecA1
and Thr532 are identied as the main anchoring points of the
two domains. The base between these two threonine residues is
coordinated by the backbone NH of His311, an interaction which
is conserved in NA containing crystal structures. Ser310 is also
reasonably conserved, although not directly involved in ssRNA
coordination in this state of the enzyme.
Interestingly, the most conserved motif across the sequences
is a GDP(A)Q loop interfacing between the RecA1 and RecA2
domains. This motif features Gln404, a residue which we
consider to be important in the coordination of the nucleophilic
water in the ATP binding pocket; moreover, it bridges the ATP g-
phosphate and the SH motif discussed earlier. We speculate
these moieties play a role in the translocation of the RecA2 unit
upon ATP hydrolysis.MD simulations
ATP binding site. We extracted nine key distances (Fig. 4a
and S3†) along the simulations from our unbiased trajectories
of the ATP-ssRNA-helicase (holo) complex. There is an overall
good agreement between the two force elds for the distribu-
tion of these contacts. The hexacoordinate Mg2+ shows stable
coordination to 3 water molecules, the OH of Ser288 and
oxygens from the b- and g-phosphates of the ATP (Fig. S3a–c†),
which is essential for the preorganization of the ATP hydrolysis.
Further conserved contacts in the pocket are also maintained© 2021 The Author(s). Published by the Royal Society of Chemistry


























































































View Article Onlineduring the simulation including the arginine ngers (Fig. S3g
and h†), Lys288 (Fig. S3i†) and the DE motif (Fig. S3d and e†)
which both takes part in coordinating the Mg2+ and the nucle-
ophilic water. The largest deviations between CHARMM and
AMBER force elds are observed for the Gln404 and ATP
distance (Fig. S3f†). This is a particularly important conserved
residue that likely coordinates the attacking water. Using the
CHARMM fore eld, Gln404 shows greater exibility deep in the
ATP pocket, which might support a role in changing the protein
conformation during translocation. Residues participating in
the adenosine base coordination are less conserved and form
fewer stable contacts.
RNA binding site. From the structural analysis and the
homology modelling, we denote two important and well-
conserved interactions between the ssRNA and the helicase.
Both interactions involve a H-bond between a threonine
(Thr359 from RecA1 and Thr532 from RecA2) and a phosphate
oxygen on the backbone of the ssRNA. Additionally, another H-
bond is made between the central RNA residue and the N of
His311, this residue is moderately conserved and the interac-
tion between its backbone and the phosphate oxygen of the RNA
is present in several PDB structures. A key residue close to the
RNA pocket is Ser310; this residue is conserved (oen present as
a threonine) and appears to be important for the communica-
tion between the ATP pocket and the RNA pocket (Fig. 4c and d).
The stability and dynamics of the RNA have been further
analysed by looking at the furanose ring conformation. The
denition of the envelope conformers and the puckering angles
as descriptors of the conformation are discussed in the ESI NoteFig. 5 (a) 2D free energy profile along with the puckering angle and the d
holo simulations. The colour bar represents the hight of the free energ
minima, showing uracil 6 in grey sticks and threonine 359 as yellow sticks.
(b and c) Distribution of the puckering angle along the MD simulations us
(c).
© 2021 The Author(s). Published by the Royal Society of Chemistry3. RNA nucleotides, differently from DNA nucleotides, usually
adopt a C30-endo conguration (usually dened as N), and they
become less stable/more reactive when switching to a C20-endo
conguration (dened as S). From a structural comparison with
the PDB structure with NA bound to helicase, we can see that
most nucleotides present a C20-end conguration (Fig. S5†). We
calculated the puckering value in our MD simulations, as ex-
pected most of the nucleotides, present a C30-endo congura-
tion, relatively stable along with the simulations (Fig. 5 and
S4†). Uracil 5, 6 and 7 present a bimodal distribution, showing
during multiple trajectories both N and S conguration. Using
2D-DHAM, we calculated the free energy surface by correlating
the puckering angle of uracil 6 and the distance between the
phosphate oxygen of uracil 6 and the g-oxygen of Thr532
(Fig. 5a). The reconstruction of the corresponding free energy
prole is not possible using the CHARMM trajectories, because
the transition between the puckering states is not sampled well.
This implies that the CHARMM force eld describes the RNA
residues more rigidly. We also observe a difference in the
orientation of the 30 terminal residues (Ura7 and Ura8) between
force elds, while the rest of the ssRNA behaves similarly and
agrees well with the experimental structure (Fig. S6†).Principal component analysis
To understand the key structural components corresponding to
the longer time-scale thermal motions of the protein in the holo
(with both ATP and ssRNA bound) and apo forms, we performed
principal component analysis. For all simulations analysed, theistance between uracil 6 (OP1) and threonine 359 (OG), from all Amber
y profile in kcal mol1. Insets depict the structures in the three local
Specific distance between the residues is highlighted by yellow dashes.
ing CHARMM (blue) and Amber (orange) force field for uracil 3 (b) and 6
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View Article Onlinerst four PCA components always accounted for greater than
80% of the observed variance, we therefore focused our analysis
on these.
Key observations are shown in Fig. 6, S7 and S8,† which
provide a direct comparison between the apo and holo mono-
mer simulations. The weighted RMSD modes for the rst four
PCA components show the residue displacements captured by
each component (Fig. 6a and b and S7†) for the apo and holo
simulations, respectively. To reveal the correlated motion
within the protein, DCC maps were generated using the rst
PCA component, which accounts for the largest portion of the
overall observed variance (Fig. 6c and e, and S8†).
Increased exibility in the RecA2 domain is the most clear
and signicant difference present between the apo and holo
data (Fig. 6a and b for Amber and, consistently, in Fig. S7† for
CHARMM). Residues around the RecA1 interface and ATP
binding site, most notably in the outermost loop from Thr450 to
Ala510, are more exible in the absence of ATP, as is clear fromFig. 6 (a and b) Comparison of PCA Weighted-RMSD scores holo mono
holo monomer simulation with Amber. (d) Key areas highlighted in the h
arrows indicating relative change in magnitude): (A) Zinc Binding region
interface loop from Thr450 to Ala510 (red). Bound objects are shown and
(left spheres) and magnesium as a yellow sphere. (e) DCC map of apo
principal component. Colour bar providing correlation scale is shown in
13500 | Chem. Sci., 2021, 12, 13492–13505the magnitude of the associated weighted RMSD mode (Fig. 6a
and d; label C, red). This observed exibility is also consistent
with the increased experimental beta-factors of this region for
the 6jyt and 6zsl structures (ESI note 3 and Fig. S9†). On the
other hand, the presence of ATP in the holo simulations stabi-
lizes many of the key residues involved in binding along with
the whole of the RecA2 domain (Fig. 6a and b), as it is indicated
by the decreased weighted RMSD in the holo simulations and
thus smaller contribution to all the PCA components.
The behaviour of the loop from Ile334 to Gln354 is another
key difference between holo and apo simulations. This is more
prevalent in the Amber simulation PCA components (Fig. 6a
and d; label B, purple) and visible as the large cross in the DCC
maps (Fig. 6c), which shows its motion differs from the rest of
RecA1. Its position between both key RNA binding residues
(Thr359 and Thr532) and ATP binding residues (such as Lys320)
point towards the substrates providing some tension keeping
this loop in place. The stable orientation and position of themer (a) and apo monomer (b) simulations with Amber. (c) DCC map of
elicase structure (d, grey cartoon) and on panels a and b (text box and
(green), (B) Domain 1 loop from Ile334 to Gln354 (purple), (C) RecA1/2
coloured: RNA in blue (centre), ATP in lime (upper right), zinc in orange
monomer simulation with Amber for motions described by the first
the bottom centre.
© 2021 The Author(s). Published by the Royal Society of Chemistry


























































































View Article Onlinesidechain Lys345 observed during holo simulations alludes to
an interaction with either the nearby a-helix containing Lys320
or the ATP binding site itself.
In the holo simulations, PCA identies more uctuations
from regions in the ZBD (Fig. 6b and d; label A, green). The holo
DCC map (Fig. 6e) highlights the predominant conformational
motion in the rst PCA component, splitting the helicase intoFig. 7 Overview of binding pockets (coloured surfaces) identified in
the holo complex MD trajectories. ATP (grey sticks) and the ssRNA
(cartoon) are only show for the sake of orientation.
Table 1 Occurrence and volume statistics of pockets depicted in Fig
experimental structures represent the different chains. Note that the mi
Force eld ATP pocket RNA pocket RecA
(%) Holo CHARMM 96.28 98.60 18.45
Amber 98.28 98.18 34.92
Apo Amber 81.40 99.74 35.06
Volume (stdev)/Å3 Holo CHARMM 630 (263) 1472 (858) 276 (
Amber 542 (223) 1911 (565) 330 (
Apo Amber 665 (338) 2415 (873) 303 (
6jyt X-ray 4058 334
4427 1282a
6zsl 474 + 267b — —
613 — —
6xez Cryo-EM 534 3698 662
4891 540
7cxm 708 2780 588
782 1566 —
a Labelled pockets are connected, the combined volume is shown. b Mad
© 2021 The Author(s). Published by the Royal Society of Chemistrythree correlated areas: (i) the ZBD domain, (ii) the rest of
Domain 1 along with RecA1, and (iii) RecA2. The structure
oscillates with the ZBD and RecA2 regions moving in correla-
tion, opposing the larger central region. All bound simulations
showed this global motion (Fig. S10†), displaying an increased
exibility in loops around the ZBD domain not directly involved
in zinc-binding and a larger correlation across the motion of the
RecA2 domain. However, while the scale of these movements
does not indicate a domain level change, it is indicative of the
protein exibility otherwise not easily accessible from e.g.,
crystallographic data, and disrupting this major motion may
provide an aim for future inhibitor design.
Pocket analysis
We selected cavities that were consistently present in our MD
simulations and tracked the changes in these pocket volumes
during the trajectories (Fig. 7). The average volumes and cor-
responding standard deviations of the pocket sizes in different
simulation types are also compared with available experimental
structures in Table 1. The distributions of the pocket volumes
are depicted in Fig. S9 and S10† for the holo and apo systems,
respectively.
Substrate pockets. The ATP pocket is easily identied in the
holo trajectories and its volume is 600 Å3. In the apo trajec-
tories the standard deviation increases, indicating less con-
strained movement between RecA1 and RecA2. The RNA pocket
is usually the largest cavity identied and ranges along the
interface between the domains, largely overlapping with the
RNA binding site. The volume of the RNA pocket increases from
1911 (1472 with CHARMM) to 2415 Å3 in the apo trajectories
compared to the holo structures (Table 1), which can be
attributed to the larger freedom in the movement of the
domains as the RNA goes along the interface. Additional data
on the apo dimer simulations are also available in Table S5.†
The 6jyt crystal structure features a connected ATP-RNA
pocket in both of the monomer chains, as is oen observed in. 7 in MD simulations and available PDB structures. The rows in the
nimum volume for any pocket to be defined is 200 Å3
2 pocket1 RecA2 pocket2 RecA2 pocket3 Stalk pocket ZBD pocket
22.25 54.57 26.52 16.91
18.12 — 16.40 20.26
— 37.00 17.77 7.89
64) 409 (179) 405 (200) 449 (202) 268 (74)
91) 353 (119) — 300 (75) 246 (47)
106) — 286 (99) 282 (73) 247 (50)
204 — — —
— 1282a — —
— — — —
— — — —
— — 279 —
— — — —
369 — — —
— — — —
e of two separate pockets.
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View Article Onlineour apo simulations (Fig. S13†). In general, the sizes of the ATP
and RNA pockets agree between the crystal structures and our
simulations, including a decrease in the RNA pocket size when
ssRNA is bound to the structure (holo, 7cxm in Table 1).
Allosteric pockets. Generally, all non-substrate pockets are
signicantly smaller, and appear less frequently during the
trajectories. Among the RecA2 pockets, pocket1 is the most
consistent, while both pocket2 and pocket3 depends on the
movement of the C-terminus of the chain and they are sensitive
to the presence of the natural substrates or the force eld (see
Table 1 and S5†). Pocket1 is also found in most of the experi-
mental structures by our pocket analysis.
Domain 1 hosts two interesting pockets, the ‘Stalk pocket’
and ‘ZBD pocket’. The Stalk pocket resides between the longer
Stalk helix and the ZBD and can be consistently identied in all
trajectories, although its average volume varies, probably
because it is close to the N-terminus of the chain, which moves
relatively freely. More importantly, several bound molecules
were identied at this site experimentally in the helicase-smallFig. 8 Free energy profiles depicted along selected coordinates and su
Gly287-Arg443 distance and ATP pocket volume. The color bar represen
(black surface) and the Gly287-Arg443 distance (residues in green, dista
Gln404-Asn563 distance and RNA pocket volume. The color bar repre
pocket (cyan surface) and the Gln404-Asn563 distance (residues in gree
13502 | Chem. Sci., 2021, 12, 13492–13505molecule crystal structures deposited in the PDB (5rli, 5rmd and
5rm1). The Stalk pocket is also identied in one of the cryo EM
structures (PDB 6xez). The ZBD pocket is found in most
trajectories but in the lowest consistency and average volume
among all analysed pockets. The residues neighbouring these
pockets are detailed Fig. S14†. Overall, both force elds iden-
tied the pockets with similar statistical parameters. One
difference was in the additional pocket3 observed in RecA2 with
CHARMM that is absent from Amber.Features inuencing the pocket volume
We examined the correlation between the volume of the iden-
tied pockets and the residue–residue distances in the trajec-
tories (ESI note 5 and Table S6†). This enables us to detect the
mechanism and elucidate the precise structural interactions
leading to these cavities opening up and closing during the MD
simulations. Subsequently, we also calculated the quantitative
free energy proles related to these correlations using DHAM.bstrate pocket volumes (holo Amber trajectories). (a) 2D profile along
ts the height of the free energy profile in kcal mol1. (b) The ATP pocket
nce in blue) depicted in a representative structure. (c) 2D profile along
sents the height of the free energy profile in kcal mol1. (d) The RNA
n, distance in blue) depicted in a representative structure.
© 2021 The Author(s). Published by the Royal Society of Chemistry


























































































View Article OnlineThe ATP pocket is located at the interface of RecA1 and
RecA2, thus it primarily depends on the interactions of the
contacting residues. We observed that the opening of the pocket
can be described by the distance between Gly287 or the P-loop
and the arginine nger 443, resulting in three connected local
minima on the potential energy surface (Fig. 8a and b).
On the other hand, the RNA pocket is larger, it has more
bordering residues and it can open up in multiple directions.
Here, as one of the most prominent directions, we focus on the
inuence of the contact between Asn563 and Gln404, which is
anti-correlated with the size of the RNA pocket. Gln404 is
located in one of the most conserved motifs in the sequence
(Fig. 3b) and it is connected to the ATP g-phosphate (Fig. 4c),
directly inuencing the ATP hydrolysis. The increase of this
Asn563-Gln404 distance decreases the optimal RNA pocket size
by 500 Å3 down to 1500 Å3 (Fig. 8c and d).
Conclusion
Here, we present structural and sequence comparison studies,
as well as molecular dynamics simulations of both the apo and
a catalytically relevant computational model of the SARS-CoV-2
NSP13 ATP dependent RNA helicase. The analysis of homolo-
gous sequences sheds light upon the specicity of the domain
structure of the viral helicase yielding nomatch over 20% except
close relatives from the coronaviridae family.
We performed extensive MD simulations of helicase mono-
mers and a dimer. However, upon analysis of available experi-
mental structures, including the RTC complex, we suggest that
the dimer is not the functional unit, and we furthermore
focused on the monomer.
To gain key insights into the structure and dynamics of the
complete holoenzyme in addition to the experimentally avail-
able apo protein, we modelled a fully assembled complex with
both the ATP and ssRNA substrates. The structure of the ATP
pocket was reconstructed including signature motifs from
phosphate binding proteins, such as the DE(AD) of helicases,
the P-loop, and arginine ngers. We did not observe large scale
domain level motions upon RNA binding. Nevertheless, some
conformational changes are required to accommodate the RNA,
which, compared to the ATP, does not have so well-dened
interactions with the protein to enable multiple sequences to
be processed. Moreover, more structural variations and uncer-
tainties for the RNA are also observed in our models during the
simulations. Importantly, we identied highly conserved
anchoring points in the core of the helicase for polynucleotide
binding, which are essential to understand the translocation
driving the unwinding activity of NSP13. Our molecular
dynamics simulations veried the stability of conserved inter-
actions in our model, as well as improved our initial model to
host the nucleic acid. Decomposing the trajectories into prin-
cipal components highlighted the rigidifying effect of the
substrates to the protein structure. The increased stability of
our holoenzyme model should be exploited in subsequent
docking studies, moving away from the apo structures.
We characterized the volume of the ATP and ssRNA pockets
and, importantly, identied additional allosteric binding sites.© 2021 The Author(s). Published by the Royal Society of ChemistryWe assessed the connection between the substrate pockets and
key interactions therein, giving insights to the dynamic behav-
iour of the cavities. Importantly, we found pockets in the highly
specic Domain 1 of the helicase which coincides with some
experimentally bound substrates. This may provide a good
opportunity for specic structure-based inhibitor design.
The comparison of different force elds resulted in small
differences only. CHARMM presents a more rigid ssRNA model
than Amber, leading to less structural diversity when consid-
ering the bound RNA conformation. The ATP binding on the
other hand remains robust in all holo simulations with both
force elds. The change in the dynamics of the protein upon
substrate binding is similar, as well as the qualitative descrip-
tion of allosteric pockets.
Our work provides insight into a key participant of the SARS-
CoV-2 viral replication machinery, one of the prominent drug
targets. Our structures offer novel starting points for structure-
based compound design and screening. The catalytically rele-
vant holo structures are also ideal starting points for subse-
quent mechanistic studies of the ATPase and the unwinding
activity of the helicase. Moreover, elaborating the RNA trans-
locations driven by the identied interactions can reveal other
targetable states of the helicase.
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